Ipilimumab in Uveal Melanoma: Long-Lasting Responses in 25%Ipilimumab in Uveal Melanoma: Long-Lasting Responses in 25%
The first trial of ipilimumab in patients with uveal melanoma has shown some long-lasting responses in a patient population with poor prognosis. Medscape Medical News
Source: Medscape Dermatology Headlines - Category: Dermatology Tags: Hematology-Oncology News Source Type: news
More News: Cancer & Oncology | Dermatology | Eye Cancers | Hematology | Melanoma | Skin | Skin Cancer | Uveal Melanoma | Yervoy